Business
Why the Bionomics (ASX:BNO) share price surged 8% higher today
The Bionomics Ltd (ASX: BNO) share price has run higher today after the company announced it has entered an agreement to licence its oncology drug candidate, BNC101, to Carina Biotech. At the market’s close, the Bionomics share price had surged 8.33% to 13 cents.
What’s pushing the Bionomics share price?
The Bionomics share price has marched higher today after the company advised that it will exclusively licence BNC101 to Carina. The agreement will see the development of Chimeric Antigen Receptor T-cell (CAR-T) therapy using Bionomics’ flagship drug. CAR-T is known to harness the body’s immune system to fight against cancer.
According to the company, BNC101 is a high-quality, humanised monoclonal antibody to LGR5, which…
-
General23 hours agoIs Australia derivative? | The Spectator Australia
-
General22 hours agoDarwin hosts its first Asian Cup qualifier match, deepening cultural ties between nations
-
Business13 hours agoAiming for rock-solid retirement income? I’d buy these two ASX shares
-
General22 hours agoKatie Boulter says death threats and abuse highlight dark side of tennis betting